Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)

Trial Profile

Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Treprostinil (Primary) ; Salbutamol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
    • 15 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2020.
    • 03 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top